WEST CHESTER, Pa., June 29, 2022--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), announced that the first patient has been dosed in a clinical trial of EBTATE (177Lu-DOTA-EB-TATE) for the treatment of patients with advanced, well differentiated neuroendocrine tumors. This US based, Phase I clinical trial will evaluate the safety and dosimetry of EBTATE.
EBTATE is a patented peptide targeting radiotherapeutic drug. It selectively targets and binds to somatostatin receptor 2 on neuroendocrine tumors, which are then killed by the radionuclide. EBTATE was designed to bind to serum albumin, extending in vivo residence time, enabling lower, less frequent dosing of the radiopharmaceutical vs. the current standard of care. Early, ex.-US, clinical results in 60 patients showed EBTATE is more effective and safer for neuroendocrine tumor patients*.
Chris Pak, President & CEO of MTTI comments "This is a substantive milestone for MTTI. It marks the advent of safer, more effective, economical targeted radiotherapy drugs for neuroendocrine tumors. Recent clinical data presented at the 2022 SNMMI meeting also suggests that EBTATE treatment without the conventional amino acids infusion is safe and does no harm to kidney function, potentially, significantly improving patient comfort vs current treatments."
About Molecular Targeting Technologies, Inc. (MTTI)
Molecular Targeting Technologies, Inc. is a privately held, rapidly growing, well financed, clinical stage biotech developing next-generation targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2022. For more information: www.evathera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005167/en/